Now showing items 1-10 of 127
Extensive Skin Necrosis Induced by Low-Molecular-Weight Heparin in a Patient With Systemic Lupus Erythematosus and Antiphospholipid Syndrome
(Lippincott Williams & WilkinsPhiladelphiaEUA, 2012)
US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins
Low-molecular-weight heparins (LMWHs) have shown equivalent or superior efficacy and safety to unfractionated heparin as antithrombotic therapy for patients with acute coronary syndromes. Each approved LMWH is a pleotropic ...
Perioperative Management of Long-Term Warfarin Anticoagulated Patients (Focused on Outpatient Bridging with Low Molecular Weight Heparins)Manejo perioperatorio de la anticoagulación en pacientes tratados crónicamente con warfarina (con énfasis en la sustitución ambulatoria con heparinas de bajo peso molecular)
Combinations of low doses of unfractionated heparin and of low-molecular-weight heparin prevent experimental venous thrombosis
Synergism between low-molecular-weight heparin and low doses of unfractionated heparin (UH) enhancing anti-factor Xa activity and the release of tissue factor pathway inhibitor was observed. The aim of this study was to ...
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
(Cochrane Collaboration, 2015)
This is the protocol for a review and there is no abstract. The objectives are as follows: To examine the existing clinical evidence on the efficacy of prophylactic anticoagulation with direct factor Xa inhibitors versus ...
Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells
(Associação Brasileira de Divulgação Científica, 2001-06-01)
The anticlotting and antithrombotic activities of heparin, heparan sulfate, low molecular weight heparins, heparin and heparin-like compounds from various sources used in clinical practice or under development are briefly ...
Heparinas de bajo peso molecular en pacientes con enfermedad renal crónica ¿Es seguro su uso?
(Sociedad Médica de Santiago, 2010)
Estudos de medicamentos biosimilares
In Brazil, the registration of new drugs is carried out only when the regulatory agency (Anvisa, acronym in Portuguese) is fully satisfied with the evidence of their quality, efficacy and safety, presented by a pharmaceutical ...